PCM
AIMT

Prelude Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

Prelude Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-219,893
Closed -$7.58M – 2277
2020
Q3 		$7.58M Buy
+219,893
New +$4.68M 0.37% 36

Prelude Capital Management's AIMT Position: Q4 2020 in Review

Prelude Capital Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 219,893 shares — an estimated $7.58M sold.

Prelude Capital Management first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $7.58M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Prelude Capital Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Prelude Capital Management sold 219,893 Aimmune Therapeutics shares in Q4 2020, an estimated $7.58M.
  • Prelude Capital Management first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
  • Prelude Capital Management's Aimmune Therapeutics position peaked at $7.58M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.